Dr. Michelle Monje
speaker
133 appearances
1 recordings
1 series
first heard Jul 2026
last heard 31 Jul
Dr. Michelle Monje’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.
Appearances
And so screening those patient-derived cell cultures that we had from my patients, we identified one particular target that was very, very highly expressed in diffuse methionine gliomas.
It's called GD2.
And then after identifying that, I reached out to a colleague of mine at Stanford and together we started testing her CAR T cells targeting GD2 in our models of diffuse midline glioma and found now nearly 10 years ago that in the mouse models, the CAR T cells cured the mice, cleared all the tumors.
It was really remarkably effective.
We brought that to clinical trial six years ago, beginning in the spring of 2020.
And we've been treating children with GD2-targeting CAR T cell therapies over the last six years.
And we've seen really promising signs of efficacy.
We've seen kids who've gotten better, at least for a while.
We've seen tumors shrink.
We really are heartened that this is an approach that is going to be part of a solution.
It's always harder to treat.
people than laboratory models.
And, you know, we're not seeing the rate of cures that I wish we were seeing.
But I believe that as we learn more and combine this approach with the neuroscience approaches, you know, with other medications, we'll start to really make transformative progress.
So as a field, everyone is working on different aspects.
And the challenge now is to bring all of those different potential and promising therapeutic approaches together in the right combination.
What keeps you going?
My patients.
We have to find a solution to these terrible cancers.
They deserve better.
Showing 101–120 of 133 · page 6 of 7
← Previous
Next →